In 2001, using NH2-specific MET antibodies, Nath et al. demonstrated that lysophosphatidic acid (LPA), a serum phospholipid and GPRC ligand, and EGF, a mitogenic growth factor acting through transmembrane tyrosine kinase receptors, increase MET ectodomain shedding in A549 human lung adenocarcinoma cells. This evidence concerns the gene MET and lung adenocarcinoma.